Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
AssigneeThe Board of Regents of the University of Oklahoma
InventorsRichard Cummings, Rodger McEver
Life of this patent
Estimating the term…
Abstract
Compounds, compositions and methods for treating conditions characterized by leukocyte rolling are described. The compounds contain glycosulfopeptide structures comprising sulfated tyrosines and sialyated, fucosylated N-acetyllactosamino glycans. The glycosulfopeptides may be conjugated or complexed to other compounds for enhancing serum half-life or for controlled release, for example. Examples of conditions treated include inflammation, ischemia-reperfusion injury, rheumatoid arthritis, atherosclerosis, leukocyte-mediated lung injury, restenosis, and thrombosis.
Claims6
A method of inhibiting or reducing leukocyte rolling in a subject in vivo, comprising:
- administering to the subject an effective amount of a compound comprising a glycosulfopeptide thereby inhibiting or reducing leukocyte rolling in the subject, the glycosulfopeptide comprising the structure:
- wherein C is an O-, N-, or S-linking amino acid;
- and
- wherein R is one of R1, R3-R13 or R15 wherein:
A composition for inhibiting or reducing leukocyte rolling in a subject in vivo, comprising:
- a pharmaceutically acceptable carrier;
- and
- a compound comprising a glycosulfopeptide comprising the structure:
- wherein, C is an O-, N-, or S-linking amino acid;
- and
- wherein, R is one of R1, R3-R13 or R15 wherein:
Dependencies are inferred from the claim text.